Introduction

The Transplantation and Cellular Therapy Certified Nurse (TCTCN) credential — formerly known as BMTCN — is administered by the Oncology Nursing Certification Corporation (ONCC). It validates specialized knowledge in hematopoietic stem cell transplantation (HSCT) and cellular therapy. If you’re considering this certification, here’s an honest assessment of its difficulty.

Exam Structure

• •Questions: 165 multiple-choice (125 scored, 40 unscored pretest)
• •Time Limit: 3 hours
• •Passing Score: Scaled score of 55 (25–75 scale)
• •Format: Computer-based testing at PSI testing centers (in-person only)
• •Cost: $300 (ONS/APHON member) or $420 (non-member)
• •DoubleTake Option: Additional $100 for one retake if you fail

Eligibility Requirements

• •Current, active, unencumbered RN license
• •Minimum 2,000 hours of HSCT or cellular therapy nursing practice within the past 4 years
• •Minimum 2 years (24 months) of RN experience within the past 4 years
• •Minimum 10 contact hours in HSCT or cellular therapy nursing within the past 3 years

---

Pass Rate Analysis

ONCC does not publicly publish TCTCN-specific pass rate data in detail. However, based on comparable ONCC certifications:

Based on institutional data (Lurie Children’s Hospital reports 86% for CPHON) and ONCC’s general statement that “most nurses who take an ONCC certification test pass the test on the first attempt,” the TCTCN likely has a pass rate in the 70–75% range.

---

What Makes the TCTCN Exam Challenging

1. Rapidly Evolving Field

Transplantation and cellular therapy is one of the fastest-evolving areas in oncology. New cellular therapies (CAR-T, TIL, gene therapy) are being approved regularly, and treatment protocols change frequently. The exam reflects current practice, requiring knowledge of the latest therapies and evidence.

2. Complex Pharmacology

The exam tests detailed knowledge of:

• •Conditioning regimen agents: busulfan, cyclophosphamide, fludarabine, thiotepa, melphalan, TBI
• •Immunosuppressive therapy: tacrolimus, cyclosporine, methotrexate, mycophenolate, sirolimus
• •GVHD treatment: steroids, ruxolitinib, belumosudil, ibruxinib
• •CAR-T products: tisagenlecleucel, axicabtagene ciloleucel, lisocabtagene maraleucel, idecabtagene vicleucel, ciltacabtagene autoleucel
• •Supportive care: antimicrobials, growth factors, electrolyte management

3. Dual Content Tracks

The exam covers both HSCT and cellular therapy as separate content tracks (Domains III and IV each account for 22%). You need to know:

• •Traditional transplant complications: GVHD (acute and chronic), SOS/VOD, graft failure, infection
• •Cellular therapy complications: CRS, ICANS (neurotoxicity), HLH/MAS, B-cell aplasia
• •Different monitoring and management approaches for each

4. Narrow Specialty Focus

Unlike broader certifications (OCN, CCRN), the TCTCN has a very narrow practice focus. If you work in a general oncology unit rather than a dedicated transplant/cellular therapy program, you may lack exposure to some exam content.

5. Limited Study Resources

ONCC provides the test content outline, reference list, and limited practice questions. There are fewer dedicated TCTCN prep materials compared to more common certifications.

---

Difficulty Comparison

---

What Makes It Manageable

1. Focused Content Area

While the content is deep, it’s focused on one specialty area. You don’t need to know general oncology, pediatric development, or non-malignant hematology — just transplant and cellular therapy.

2. Predictable Exam Structure

ONCC publishes the exact domain weights. Four clinical domains are equally weighted at 22% each, so you can study proportionally.

3. Clinical Experience Is Essential

If you’ve been working in a transplant or cellular therapy program for 2+ years, much of the exam content will be familiar. The 2,000-hour eligibility requirement ensures candidates have substantial clinical exposure.

4. DoubleTake Safety Net

For $100, you get a guaranteed retake. This reduces the financial risk of the first attempt.

---

Tips to Pass on Your First Attempt

• •Focus on the four clinical domains (88% of exam): Foundations, Process, Post-HSCT, and Post-Cellular Therapy
• •Master CRS and ICANS grading: These are the most tested cellular therapy complications
• •Know your CAR-T products: Indications, manufacturing timelines, CRS risk profiles, monitoring requirements
• •Study GVHD thoroughly: Acute vs. chronic, NIH grading, organ involvement, first-line and second-line treatment
• •Create comparison charts: Autologous vs. allogeneic, CAR-T vs. HSCT, acute vs. chronic GVHD
• •Use the ONCC Test Reference List: These are the exact sources used to write exam questions